Facebook
Google+
http://www.inovotion.com/publications/newsletter-2/newsletter-october-2020">
Twitter
LinkedIn

October 2020

New webinar

Preclinical Evaluation of Anti-metastatic Drug Candidates using a Next-Generation Chicken Embryo Model

December 3rd  11AM New York -  5PM Paris

Dr Chloé Prunier, R&D Department, INOVOTION

We're pleased to have Dr Chloé Prunier, who will discuss:

  • Benefits of early in vivo efficacy evaluation to optimize the probability of success for anti-metastatic drug candidates
  • Description of our chicken embryo model and its characteristics
  • Benefits of this model for filling the gaps between in vitro and mouse models
  • Comparative analysis with the mouse model
  • Metastatic processes in our chicken embryo model
  • Case studies 
PROGRAM & REGISTRATION

Credit: publication authors

The latest publication led by Dr. Anna Halama, Assistant Professor of Research in Physiology & Biophysics at Weill Cornell Medicine - Qatar,  featured on the front cover of Metabolites journal 

"The Inovotion's CAM model has the advantage of costing less and being faster than using mice, while at the same time being much more reliable than simpler cell culture techniques. It is a robust method, and we were willing to work on already established protocols"

Led by Dr. Anna Halama, Assistant Professor of Research in Physiology & Biophysics, the WCM-Q team combined the already established laboratory technique of implanting cancerous cells into chicken embryos (called in ovo research) with a powerful biochemical analysis method called metabolomics. These two innovative research techniques are combined in a new testing platform that not only gives deeper insights into the ways in which certain types of cancers resist chemotherapy drugs and proliferate, but also delivers significant cost and time savings over existing research methods. The research is considered such a significant breakthrough that it was featured on the front cover of Metabolites, one of the industry’s leading scientific journals. The in ovo technique also has the advantage of costing less and being faster than using mice, while at the same time being much more reliable than simpler cell culture techniques.

Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo

Metabolites 2020, 10, 268 

(With the courtesy of Weill Cornell Medicine Qatar)

Credit: publication authors

R&D Booster project: a 900k€ project for deepening our understanding of cancer mechanisms and other diseases 

High-potential biotechs Inovotion and LXRepair specialized in DNA repair assays  have partnered with Grenoble-Alpes University Hospital and the Institut for Avanced Biosciences (IAB) in a 900k€ R&D contract awarded by the Auvergne Rhone-Alpes region.  

The project coordinated by Inovotion’s R&D department will develop a disruptive new method for screening and validating new drugs, to widen and accelerate the development of new therapies for cancer and other diseases. The new method will also allow precision-medicine screening of patients, to select treatments based on their response to specific drugs.

FAQ:

Can experiments to study metastasis be conducted on Inovotion's model?

Yes. We can perform metastatic invasion analysis on individual organs like brain, liver, lung, kidney etc., based on your organs of interest pertaining to the type of studied cancer. Routinely, this assay is done using the lower chorioallantoic membrane and could be performed, on demand, for different organs.

FAQ

Meet our team

Every year our Business Development team attends many events to meet potential customers and partners. In 2020, we switched Online Events which are a viable and valuable alternative.

Feel free to contact us to plan a meeting either during the events listed below or to discuss with our experts.

ABOUT US

Optimizing your preclinical and Drug Discovery studies is of prime importance, and INOVOTION has developed a solution based on its unique and cutting-edge in vivo technology.

As a Contract Research Organization (CRO) dedicated to in vivo evaluation for Drug Discovery mainly in oncology, INOVOTION is a sought-after partner for Pharma and Biotech companies as well as academic labs all over the world.

Our main missions are to:

  • Help you find the best candidate anti-cancer treatment
  • Detect the first in vivo toxicity effects of your candidate compounds
  • Improve productivity and Return-On-Investment of your preclinical and Drug Discovery process by maximizing your lead optimization phase

Accelerate the overall Drug Discovery process to answer unmet medical needs in oncology.

Any questions about Inovotion's technology? Contact us at

contact@inovotion.com

INOVOTION SAS
HQ & Lab Facilities

+33 475 549 512

5 ave du Grand Sablon
38700 La Tronche
France

INOVOTION Inc

185 Alewife Brook Parkway, Suite 210
Cambridge, MA 02138

USA

Facebook
Google+
http://www.inovotion.com/publications/newsletter-2/newsletter-october-2020">
Twitter
LinkedIn

Register for our Newsletter